Strattera
Indicated to support cognitive function in attention deficit hyperactivity disorder, formulated to address executive dysfunction and alleviate impulsivity during daily activities.
Strengths: 10 · 18 · 25 · 40mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Selective Norepinephrine Reuptake Inhibitor
- Pharmacological class
SNRI
- Minor side effects
nausea; vomiting; decreased appetite; dry mouth
- Moderate side effects
insomnia; tachycardia; palpitations; irritability
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Eli Lilly
- Onset Time
2–4 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature in a dry place.
- Drug interactions
MAO inhibitors; salbutamol; antihypertensives
- Age restrictions
Not recommended for children under 6 years of age.
Contraindications
hypersensitivity to atomoxetine; narrow-angle glaucoma; severe cardiovascular disorders; concurrent use of monoamine oxidase inhibitors; phaeochromocytoma
Precautions and warnings
monitor blood pressure and heart rate; monitor for suicidal ideation in children; avoid use if pre-existing heart conditions present
Serious side effects
liver injury — requires immediate medical attention; arrhythmia — requires immediate medical attention; suicidal ideation — requires immediate medical attention
Patient summary
Indicated to support cognitive function in attention deficit hyperactivity disorder, formulated to address executive dysfunction and alleviate impulsivity during daily activities.
Mechanism of action
Atomoxetine acts as a selective inhibitor of the presynaptic norepinephrine transporter. By preventing the reuptake of norepinephrine, it increases the neurotransmitter's concentration in the synaptic cleft, particularly in the prefrontal cortex, thereby enhancing attention and impulse control.
Pregnancy and breastfeeding
Not recommended during pregnancy unless clearly necessary. Consult a physician regarding breastfeeding.
Strattera
Indicated to support cognitive function in attention deficit hyperactivity disorder, formulated to address executive dysfunction and alleviate impulsivity during daily activities.
Editorial Notes
- Active ingredient(s): Atomoxetine
- Listed indication(s): Attention Deficit Hyperactivity Disorder
Usually available as
- 180 tablets - 10 mg221-10-mg-5245
- 60 tablets - 18 mg221-18-mg-8501
- 60 tablets - 25 mg221-25-mg-5248